Kyongbo Pharmaceutical Co Ltd Market Cap ($83.11 Million)
Market Cap & Net Worth: Kyongbo Pharmaceutical Co Ltd (214390)
Kyongbo Pharmaceutical Co Ltd market cap. Kyongbo Pharmaceutical Co Ltd (KO:214390) has a market capitalization of $83.11 Million (₩122.64 Billion) as of November 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19725 globally and #1014 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kyongbo Pharmaceutical Co Ltd's stock price ₩5130.00 by its total outstanding shares 23906860 (23.91 Million). Also see Kyongbo Pharmaceutical Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Kyongbo Pharmaceutical Co Ltd Market Cap History (2015–2026)
Kyongbo Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $210.25 Million to $83.11 Million (-7.91% CAGR). Check Kyongbo Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Kyongbo Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kyongbo Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Kyongbo Pharmaceutical Co Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Kyongbo Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.51x
Kyongbo Pharmaceutical Co Ltd's market cap is 0.51 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $209.59 Million | $186.73 Billion | $12.71 Billion | 0.00x | 0.02x |
| 2017 | $192.39 Million | $191.66 Billion | $17.96 Billion | 0.00x | 0.01x |
| 2018 | $160.34 Million | $201.34 Billion | $13.12 Billion | 0.00x | 0.01x |
| 2019 | $130.81 Million | $191.71 Billion | $5.29 Billion | 0.00x | 0.02x |
| 2020 | $260.59 Million | $215.29 Billion | $9.40 Billion | 0.00x | 0.03x |
| 2021 | $172.14 Million | $170.66 Billion | -$7.50 Billion | 0.00x | N/A |
| 2022 | $161.05 Million | $196.26 Billion | $610.59 Million | 0.00x | 0.26x |
| 2023 | $135.93 Million | $216.36 Billion | $2.97 Billion | 0.00x | 0.05x |
| 2024 | $100.77 Million | $238.56 Billion | $4.64 Billion | 0.00x | 0.02x |
| 2025 | $93.48 Million | $264.10 Billion | $182.29 Million | 0.00x | 0.51x |
Competitor Companies of 214390 by Market Capitalization
Companies near Kyongbo Pharmaceutical Co Ltd in the global market cap rankings as of November 4, 2026. Also see 214390 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Kyongbo Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Kyongbo Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Kyongbo Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Kyongbo Pharmaceutical Co Ltd's market cap moved from $210.25 Million to $ 83.11 Million, with a yearly change of -7.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩83.11 Million | -11.09% |
| 2025 | ₩93.48 Million | -7.23% |
| 2024 | ₩100.77 Million | -25.86% |
| 2023 | ₩135.93 Million | -15.60% |
| 2022 | ₩161.05 Million | -6.45% |
| 2021 | ₩172.14 Million | -33.94% |
| 2020 | ₩260.59 Million | +99.21% |
| 2019 | ₩130.81 Million | -18.42% |
| 2018 | ₩160.34 Million | -16.66% |
| 2017 | ₩192.39 Million | -8.21% |
| 2016 | ₩209.59 Million | -0.31% |
| 2015 | ₩210.25 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Kyongbo Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $83.11 Million USD |
| MoneyControl | $83.11 Million USD |
| MarketWatch | $83.11 Million USD |
| marketcap.company | $83.11 Million USD |
| Reuters | $83.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more